{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"technology_type":["HiSeq X Five, ILLUMINA"],"study_type":["Whole Genome Sequencing"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001002755"],"host":["EGA"],"description":["EGA study EGAS00001002755"],"dataset_title":["iPSC variation file (VCF) for EBiSC","iPSC alignment file (CRAM) for EBiSC","iPSC Samples for EBiSC"],"category":["restricted"],"repository":["EGA"],"name_synonyms":["other disease, d230, Fibroblast-Derived IPS Cell, Activity, Laboratory, Induced Pluripotent Stem Cell, IPS, Addresses, Fibroblast Derived IPS Cells, hiPSC, dTAFII250, EfW1, IPS Cells, AI451642, BANK, dmTAF[[II]]230, Caucasian, diseases, dmTAF1, Taf230, disease or disorder, diseases and disorders, iPS cell, Research Activity, Laboratory Research, TAF250, Priorities, Fibroblast-Derived IPS Cells, study, Taf200, human disease, Complete, Occidental, dTAF[[II]]250, Whole Genome, reference sample, TFIID TAF250, Research, cel, cell, Complete Genome Sequencing, Taf1p, Sequencing, Human Induced Pluripotent Stem Cells, non-neoplastic, dTAF250, Whole, disorder, Homo sapiens disease, Development and Research, Research Priority, TAF, Controlled, Controlling, dTAF[[II]]230, TAF[[II]]250, disorders, TAF200, Genome Sequencing, white, Research Priorities, l(3)84Ab, medical condition, BG:DS00004.13, TAFII-250, TAF250/230, Cell, dTAF230, TAFII250, Priority, iPSC, Complete Genome, Fibroblast Derived Induced Pluripotent Stem Cells, European, p230, Diseases, Research Activities, A530094C12Rik, TAF[[II]]250/230, condition, TFIID, selection process., IPS Cell, Caucasoid, Caucasians, Research and Development, Taf[[II]]250, TAF[[II]]230, Fibroblast-Derived IPS, TAF[II]250, Fibroblast-Derived, CG17603, TAF[[II]], Activities, disease, DmelCG17603, AVIEF, Taf250, Whites, SR3-5, Cells, Fibroblast-Derived Induced Pluripotent Stem Cells, White, Human Induced Pluripotent Stem Cell, TAF230, TAF1"],"description_synonyms":["Activity, Fibroblast-Derived IPS Cell, Laboratory, Induced Pluripotent Stem Cell, IPS, supply, Colony-Forming Units, Progenitor Cell, ino1-B, Goal, Fibroblast Derived IPS Cells, stalk, hiPSC, Development, Medication, Pharmaceutical Development, Normalcies, IPS Cells, AI451642, BANK, Caucasian, ips, Mother Cells, Scanning Transmission Electron Microscopy, Cell., IPS 1, Research Activity, iPS cell, Drug Target Prediction, primary stem, Laboratory Research, Progenitor, Normalities, Priorities, average, Fibroblast-Derived IPS Cells, Occidental, Research, distribution, scattered, Medication Development, Mother, isyna1, culm, Human Induced Pluripotent Stem Cells, retention, FATP4, Pharmaceutical, Development and Research, Research Priority, Individual Health, INO1, Colony Forming Unit, ichthyosis-prematurity syndrome, organisation, diffuse, axis, Progenitor Cells, Research Priorities, white, Scanning Transmission, Normalcy, IPS-1, Cell, Electron Microscopy, Priority, Prediction, iPSC, Colony-Forming Unit, Stem Cell, Fibroblast Derived Induced Pluripotent Stem Cells, European, ichthyosis congenita 4, Research Activities, A530094C12Rik, ino1, Individual, supply and distribution, IPS Cell, Caucasoid, Target Prediction, Drug Target Predictions, Caucasians, Research and Development, Mother Cell, Normality, storage, Stem, Fibroblast-Derived IPS, Colony Forming Units, ichthyosis congenita IV, Fibroblast-Derived, Drug, Activities, Computational Prediction of Drug-Target Interactions, Health, primary axis, AVIEF, Whites, INOS, Cells, STEM, ACSVL4, Drug Target, Fibroblast-Derived Induced Pluripotent Stem Cells, White, ino1-a, sequestering, inos, Human Induced Pluripotent Stem Cell"],"additional_accession":[]},"is_claimable":false,"name":"The European Bank for Induced Pluripotent stem cells (EBiSC) is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services.In this study Whole Genome Sequencing was performed on a selection of lines from the project.","description":"Induced pluripotent stem (iPS) cells have the potential to significantly advance drug development and health research, yet collections of stem cells are scattered across the world, their quality cannot always be guaranteed, and accessing them is often difficult. The goal of EBiSC is to establish a European iPS cell bank that will be the ‘go-to’ resource for the characterisation, storage and distribution of high quality iPS cells. Ultimately, EBiSC will become an independent organisation, distributing high quality iPS cells on a not-for-profit basis to scientists worldwide.","dates":{"updated":"2018-02-09 11:50:55"},"accession":"EGAS00001002755","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001003942","EGAD00001003934","EGAD00001003882","EGAC00001000768"]}}